Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Capital Expenditures for 6 consecutive years, with $60000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 101.66% to $60000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $60000.0, a 92.04% decrease, with the full-year FY2025 number at $60000.0, down 92.04% from a year prior.
  • Capital Expenditures was $60000.0 for Q4 2025 at Caribou Biosciences, up from -$1.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.8 million in Q2 2024 to a low of -$3.6 million in Q4 2024.
  • A 5-year average of $242500.0 and a median of $475000.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 6542.86% in 2021, then plummeted 4112.0% in 2023.
  • Caribou Biosciences' Capital Expenditures stood at $685000.0 in 2021, then crashed by 31.97% to $466000.0 in 2022, then plummeted by 70.82% to $136000.0 in 2023, then tumbled by 2752.94% to -$3.6 million in 2024, then skyrocketed by 101.66% to $60000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Capital Expenditures are $60000.0 (Q4 2025), -$1.5 million (Q3 2025), and $418000.0 (Q2 2025).